
Diego A. Díaz García/X
Mar 28, 2025, 00:13
Diego A. Díaz García: Preventing moderate to severe dermatologic AE in 1L EGFR-mutant advanced NSCLC treatment
Diego A. Díaz García, Medical Oncologist /CEO/Founder at CánCare – High Specialty in Oncology, shared a post on X:
“Preventing moderate to severe dermatologic AE in 1L EGFR-mutant advanced NSCLC treatment with amivantamab plus lazertinib COCOON Phase 2 trial.
COCOON DM reduced grade two or greater dermatologic AEs by 50% vs SoC DM.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 18:52
Mar 30, 2025, 18:31